

Highlights of This Issue 965

REVIEW

- 967 Tailoring Peptidomimetics for Targeting Protein–Protein Interactions**
 Omar N. Akram, David J. DeGraff,
 Jonathan H. Sheehan, Wayne D. Tilley,
 Robert J. Matusik, Jung-Mo Ahn, and Ganesh V. Raj

CELL CYCLE AND SENESCENCE

- 979 Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis**
 Roch-Philippe Charles, Jillian Silva, Gioia Iezza,
 Wayne A. Phillips, and Martin McMahon

CELL DEATH AND SURVIVAL

- 987 PI3K and Bcl-2 Inhibition Primes Glioblastoma Cells to Apoptosis through Downregulation of Mcl-1 and Phospho-BAD**
 Fresia Pareja, David Macleod, Chang Shu,
 John F. Crary, Peter D. Canoll, Alonzo H. Ross, and
 Markus D. Siegelin

CHROMATIN, GENE, AND RNA REGULATION

- 1002 Differential Expression of Stress and Immune Response Pathway Transcripts and miRNAs in Normal Human Endothelial Cells Subjected to Fractionated or Single-Dose Radiation**
 Sanjeevani T. Palayoor,
 Molykutty John-Aryankalayil, Adeola Y. Makinde,
 Michael T. Falduto, Scott R. Magnuson, and
 C. Norman Coleman


DNA DAMAGE AND REPAIR

- 1016 Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins**
 Susan E. Scanlon and Peter M. Glazer

GENOMICS

- 1029 Transcriptomes and shRNA Suppressors in a TP53 Allele–Specific Model of Early-Onset Colon Cancer in African Americans**
 Charles C. Weige, Marc R. Birtwistle, Himel Mallick,
 Nengjun Yi, Zuzana Berrong, Emily Cloessner,
 Keely Duff, Josephine Tidwell, Megan Clendenning,
 Brent Wilkerson, Christopher Farrell, Fred Bunz,
 Hao Ji, Michael Shtutman, Kim E. Creek,
 Carolyn E. Banister, and Phillip J. Buckhaults

ONCOGENES AND TUMOR SUPPRESSORS

- 1042 FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism**

 Jaime Acquaviva, Suqin He, Chaohua Zhang,
 John-Paul Jimenez, Masazumi Nagai, Jim Sang,
 Manuel Sequeira, Donald L. Smith,
 Luisa Shin Ogawa, Takayo Inoue, Noriaki Tatsuta,
 Margaret A. Knowles, Richard C. Bates, and
 David A. Proia

SIGNAL TRANSDUCTION

- 1055 Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3**

 Asli Muvaffak, Qi Pan, Haiyan Yan,
 Rafael Fernandez, Jongwon Lim, Brian Dolinski,
 Thi T. Nguyen, Peter Strack, Stephen Wu,
 Rossana Chung, Weiqun Zhang, Chris Hulton,
 Steven Ripley, Heather Hirsch, Kumiko Nagashima,
 Kwok-Kin Wong, Pasi A. Jänne,
 Cynthia Seidel-Dugan, Leigh Zawel,
 Paul T. Kirschmeier, Richard E. Middleton,
 Erick J. Morris, and Yan Wang




AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

Immunofluorescence picture (200×) of a murine papillary thyroid carcinoma stained for galectin-3 (green) and DAPI (blue). This mouse model, developed in the McMahon Lab at the University of California, San Francisco by R.-P. Charles using the cre-activable gene *Braf*^{CA} mutant mouse coupled with a thyroid-specific cre-recombinase (*Thyro-cre*^{ERT2}), mimics closely the human pathology (e.g., galectin-3 expression). This preclinical model is invaluable for further studies using pathway-targeted drug treatments but also for uncovering the genetics behind tumor progression to anaplastic thyroid carcinoma by combining additional genomic alterations like *Pik3ca*^{H1074R} or *Pten* deletion. See the article by Charles and colleagues (beginning on page 979) for more information.



Molecular Cancer Research

12 (7)

Mol Cancer Res 2014;12:965-1066.

Updated version Access the most recent version of this article at:
<http://mcr.aacrjournals.org/content/12/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mcr.aacrjournals.org/content/12/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.